Thanks, Mike.
how the into further to to CNS unique be data alongside with the and ACTION released So, light advanced can trial, respect at shed the preclinical presentations ONCXXX of tumors. effects ONCXXX SNO, detrimental launch there
own the that that in strong highlighting these shown and at resistant a acquired presented response that therapeutic impart of studies, demonstrated compounds, role these ClpP in response target first to and the CRISPR this as conference compounds are Our can tap studies that target. to therapeutics
vivo, a with affiliated Diffuse found that researchers Gliomas, effects They ONCXXX into DMGs. in of as expression new increased immunomodulatory the [MHC X cells] dimension compound in [ph]. vitro including induces team specific DMG and a PNOC protein, abbreviated Midline of activity X unveiled of addition, In class
immune that to as by so-called DMGs new While an cold may immunostimulatory drug was context a brain. can past, ONCXXX suggest the tumor cells tumor we so published and the the system. the in immune such of findings the ability killer into on of the of immune that recognized largely in hot effects have they natural outside These be convert eliminated
understand molecular how this responses forms ONCXXX with and of HX cancer. us patients KXXM-mutant information deep and of glioma additional address in brain All could durable how ONCXXX triggers helps
Next, from. on with a recent And clinical I'll is Mike's to reminding related and let comment begin findings me follow-up what came briefly ONCXXX. compound that of where you it by
mechanism leveraging unique of So, chemistry ONCXXX from is action and the ONCXXX. emerged of medicinal a small chemical a molecule that core first-to-class structure campaign,
identify of exhibiting in minimal treating dual vitro as as against efforts direct its potency emerged that generation capable of goal campaign addressed from ONCXXX. ideal as second variety was or a advanced compound cancers, by DRDX these and cancer ClpP. The ONCXXX new to those indications beyond of therapies target new well an
activity tumors, malignancies compound from vitro are needs. the each has anti-tumor of tumors, and indication and The unmet that ONCXXX, in specific vivo CNS this been as distinct the spectrum monotherapy gynecological at verified in neuroendocrine advanced and medical of of in lead urgent forms represent
brain All of we accomplished as oral ONCXXX, window wide while quality therapeutic a patient clinic. as translate compliance, in maintaining of is well and penetration, this convenience, to life that expect Europe just the just their and the not of I by our in of experts also will have efficacy much the sounds who mentioned team us it's labs] in [own it's And in as administration compelling, collaborating validated [ph]. that U.S.
to tumor eager advanced clinic their Neuro-Oncology introduce among to pull adult the NIH, closely them molecule Community, with into the begin patients forward with escalation directly tumors. end, as To patients this was this which Chief brain the as external treatment PNOC to us to pediatric and CNS well in secured worked was that funding respectively. and dose
Their and objective extend HX is these the safety. medulloblastoma. by The such primary that beyond of work first-in-human efficacy population ONCXXX studies glioblastoma of addressed suggests establish could being KXXM-mutant as indications including to ONCXXX, monotherapy the glioma
with However, disease. that be on pilot pharmacokinetics, efficacy key would for information in cohorts will also select patients as as well gained recurrent certain
it's we While that surprises may surface scratching to are only what investigators intensify studies terms to and ONCXXX are still have schedules. from preclinical and room beyond by dose and the able what initial we escalation more achieve we pharmacokinetics The with exposure, of these No likely intensification the we profile. ahead, are in far. of heard weekly therapeutic suggest be anticipate so have its much lies in-line more safety encouraged on we still early
patient as imaging. an response activity investigator their mentioned, recurrent April in as Mike decrease glioblastoma. a investigator, recently ONCXXX patient has seen the as level per a monotherapy a Finally, in second only metabolic with radiographic the This achieved on has initiated year in as the in notified at of study and a tumor in dose last PET well response us of
XX at of evaluation potential patient months factor [ph]. doing not This clinically patient corticosteroids, removes is the was on This the continues therapy confounding on [viral imaging] and well. which in
quite ONCXXX in HX have glioblastoma harbor patient to is patient's not did KXXM-mutation. the not we this exciting date as the Importantly, HX This tumor response observed to brain a KXXM-mutation. that a lacks with a
indication broader these on continue address months and readouts developing needs this that sizable These more may future. of unmet in conferences and Overall, with these clinic to studies are ONCXXX. in to recorded to further preclinical upcoming ONCXXX expect programs we to the be profile we appropriate observed translate enroll suggests at could share currently where activity models the outside the details in the the
the turn Andriole. With call now Mike that, I'll to over
